FrancophonIA/ELRC3.0 huggingface dataset:
English: • hair loss, eczema, pruritus;
Estonian: • juustekadu, ekseem, sügelus;
English: Levetiracetam Actavis Group oral solution contains propylene glycol (E1520).
Estonian: Levetiracetam Actavis Group suukaudne lahus sisaldab propüleenglükooli (E1520).
English: Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day.
Estonian: Neljas embrüo-fetaalse arengu uuringus manustati küülikutele 200, 600, 800, 1200 ja 1800 mg/kg päevas.
English: 44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week.
Estonian: 44,6% levetiratsetaamiga ravitud patsientidel ning 19,6% platseebogrupi patsientidel täheldati partsiaalsete krambihoogude iganädalase esinemissageduse 50%-list või enamat vähenemist.
English: In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days.
Estonian: Pediaatrilistel patsientidel (1 kuu...4-aastastel) tõestati levetiratsetaami efektiivsus platseebokontrollitud topeltpimeuuringus, mis hõlmas 116 patsienti ravi kestusega 5 nädalat.
English: Respiratory, thoracic and mediastinal disorders
Estonian: Respiratoorsed, rindkere ja mediastiiniumi häired
English: Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily.
Estonian: Sõltuvalt kliinilisest vastusest ja taluvusest, võib päevaannust suurendada kuni 1500 mg-ni kaks korda päevas.
English: Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.
Estonian: Digoksiini, suukaudsete kontratseptiivide ja varfariini koosmanustamine levetiratsetaami farmakokineetikat ei mõjutanud.
English: In this study, levetiracetam dose was 3,000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.
Estonian: Selles uuringus oli täiskasvanute ja noorukite annuseks 3000 mg päevas ning laste annuseks 60 mg/kg/päevas, jagatuna kaheks annuseks.
English: 35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months.
Estonian: Platseebo-kontrolliga kliinilistes uuringutes osales 35 alla 1-aastast partsiaalsete krampidega imikut, kellest 13 olid alla 6-kuu vanused.
English: • rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase.
Estonian: • rabdomüolüüs (lihaskoe lagunemine) ja sellega kaasnev kreatiniinfosfokinaasi taseme tõus veres.
English: Levetiracetam Actavis Group treatment for as long as your doctor has told you.
Estonian: Te peate ravi Levetiracetam Actavis Group'iga jätkama nii kaua, kui arst on seda öelnud.
English: In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency.
Estonian: Raske maksakahjustuse korral võib kreatiniini kliirens varjata neerupuudulikkust.
English: A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Estonian: A. TOOTMISLOA HOIDJA, KES VASTUTAB PARTII KASUTAMISEKS VABASTAMISE EEST
English: • anorexia (loss of appetite);
Estonian: • anoreksia (isukaotus);
English: Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours.
Estonian: Ühekordse suukaudse annuse (20 mg/kg) manustamise järgselt epilepsiaga lastele (6…12-aastased) oli levetiratsetaami poolväärtusaeg 6,0 tundi.
English: Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function:
Estonian: Annuse kohaldamine neerukahjustusega täiskasvanud patsientidele ja noorukitele kehakaaluga üle 50 kg:
English: In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks.
Estonian: Pediaatrilistel patsientidel (4...16-aastastel) tõestati levetiratsetaami efektiivsus platseebokontrollitud topeltpimeuuringus, mis hõlmas 198 patsienti ravi kestusega 14 nädalat.
English: Pull the syringe by the dosing body out of the bottle (Figure 2).
Estonian: Tõmmake süstal pudelist välja (joonis 2).
English: MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Estonian: A. TOOTMISLOA HOIDJA(D), KES VASTUTAB PARTII KASUTAMISEKS VABASTAMISE EEST
English: What Levetiracetam Actavis Group is and what it is used for
Estonian: Mis ravim on Levetiracetam Actavis Group ja milleks seda kasutatakse
English: Maltitol liquid
Estonian: Vedel maltitool
English: Levetiracetam Actavis Group is not indicated in children and adolescents below 16 years on its own (monotherapy).
Estonian: Levetiracetam Actavis Group ei ole näidustatud lastele ja alla 16-aastastele noorukitele ainsa ravimina.
English: Levetiracetam Actavis Group oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).
Estonian: Levetiracetam Actavis Group suukaudne lahus sisaldab metüülparahüdroksubensoaati (E218) ja propüülparahüdroksubensoaati (E216), mis võivad tekitaad allergilisi reaktsioone (tõenäoliselt hiliseid).
English: Dose in infants (1 month to less than 6 months):
Estonian: Annusesoovitused imikutele (1 kuu vanused kuni alla 6-kuused):
English: 72.2% of the levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week.
Estonian: 72,2% levetiratsetaamiga ravitud patsientidest ning 45,2% platseebogrupi patsientidest saadi PGTC-krampide enam kui 50%-line vähenemine nädalas.
English: No enantiomeric interconversion was evidenced in vivo for either levetiracetam or its primary metabolite.
Estonian: Enantiomeeride vastastikust teineteiseks üleminekut ei leitud in vivo ei levetiratsetaami ega ka põhimetaboliidi puhul.
English: A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures.
Estonian: Topeltpimedas platseebokontrollitud pediaatrilises mittehalvemusuuringus hinnati levetiratsetaami kognitiivseid ja neurofüsioloogilisi toimeid partsiaalsete krambihoogudega lastele (4…16-aastased).
English: Should your doctor decide to stop your Levetiracetam Actavis Group treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Actavis Group.
Estonian: Kui teie arst otsustab ravi Levetiracetam Actavis Group'iga katkestada, õpetab ta teid seda tegema järk-järgult.
English: • vertigo (sensation of rotation);
Estonian: • vertiigo (pöörlemistunne);
English: Moderate
Estonian: Mõõdukas
English: Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) Levetiracetam Actavis Group 100 mg/ml oral solution contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).
Estonian: Metüülparahüdroksübensoaat (E218) ja propüülparahüdroksübensoaat (E2016) Levetiracetam Actavis Group, 100 mg/ml suukaudne lahus sisaldab metüüparahüdroksübensoaati (E218) ja propüülaparahüdroksübensoaati (E216), mis võivad tekitada allergilisi reaktsiooni (tõenäoliselt hiliseid).
English: Levetiracetam Actavis Group oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
Estonian: (1) Alla 250 mg annuste ja olukorras, mil soovitatud annus ei ole saavutatav mitme 250 mg tableti koosmanustamisel ning patsientide puhul, kes ei saa tablette neelata, tuleb kasutada suukaudset lahust.
English: Wash the syringe with water after use and close the bottle with the plastic screw cap (Figure 10).
Estonian: Pärast kasutamist peske süstal ning sulgege pudel plastik-korgiga (joonis 10).
English: The oral solution is the preferred formulation for use in infants and children under the age of 6 years.
Estonian: Suukaudne lahus on imikutel ja alla 6-aastastel lastel kasutamiseks eelistatud ravimvorm.
English: Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect.
Estonian: Levetiratsetaam kutsub paljudes loommudelites esile (partsiaalsete või esmaselt generaliseerunud haigushoogudega) krambivastase kaitse, avaldamata pro-konvulsandi toimet.
English: The other ingredients are: sodium citrate, citric acid monohydrate, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), ammonium glycyrrhizate, glycerin, glycerol (E422), maltitol liquid (E965), acesulfame potassium (E950), grape flavour (contains propylene glycol), purified water.
Estonian: - Teised abiained on: naatriumtsitraat, sidrunhappe monohüdraat, metüülparahüdroksübensoaat (E218), propüülparahüdroksübensoaat (E216), ammooniumglütsürritsaat, glütseriin, glütserool (E422), vedel maltitool (E965), kaaliumatsesulfaam (E950), viinamarja maitseaine (sisaldab propüleenglükooli), puhastatud vesi.
English: In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution.
Estonian: Selle populatsiooni (1-kuused...16-aastased) kehakaal oli märkimisväärselt korrelatsioonis ilmnenud kliirensiga (kehakaalu tõusuga tõusis ka kliirens) ja distributsiooni mahuga.
English: In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants and young children aged from 6 months to less than 4 years.
Estonian: Et olla kindel annuse täpsuses kasutatakse seda pakendit üle 6-kuu vanuste imikute ja kuni 4-aasta vanuste lastele puhul.
English: Maltitol liquid (E965) Acesulfame potassium (E950) Grape flavour (contains propylene glycol) Purified water
Estonian: Naatriumatsesulfaam (E950) Viinamarja maitseaine (sisaldab propüleenglükooli) Puhastatud vesi
English: If any bubbles appear in the syringe keep the bottle upside down and slightly push in the plunger and pull it back again.
Estonian: Kui süstlas on õhumulle, lükake ettevaatlikult süstlakolbi uuesti süstla tipu suunas, et see siis uuesti süstla täitmiseks tagasi tõmmata.
English: • abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
Estonian: • kõhuvalu, kõhulahtisus, düspepsia (ebamugavustunne), oksendamine, iiveldus;
English: For children aged 6 months to less than 4 years
Estonian: 6-kuustele kuni 4-aastastele lastele.
English: Adjustment of the dose is recommended in elderly patients with compromised renal function (see “Renal impairment” below).
Estonian: Annuse kohaldamine on soovitatav neerukahjustusega eakatel patsientidel (vt “Neerukahjustusega patsiendid”).
English: After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis.
Estonian: Ägeda üleannustamise korral tuleb magu tühjendada maoloputuse või oksendamise esilekutsumise teel.
English: As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.
Estonian: Võimaluse korral tuleb eelistada monoteraapiat, sest ravi mitme epilepsiaravimiga võib sõltuvalt kasutatavatest epilepsiaravimitest olla seotud suurema kaasasündinud väärarengute riskiga kui monoteraapia.
English: General dose: Levetiracetam Actavis Group is taken twice daily, in two equally divided doses, each individual dose being measured between 0.07 ml (7 mg) and 0.21 ml (21 mg), per kg bodyweight of the infant.
Estonian: Tavaline annus: ravimit Levetiracetam Actavis Group võetakse kaks korda ööpäevas kahes võrdses annuses, kusjuures iga mõõdetud üksikannus on 0,07 ml (7 mg) kuni 0,21 ml (21 mg) imiku kehamassi iga kilogrammi kohta.
English: No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.
Estonian: Alla 12-kuulistel epilepsiaga imikutel ei tuvastatud levetiratsetaami uusi ohutuse alaseid muutusi.
English: Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue.
Estonian: Peale selle on näidatud in vitro uuringutes, et levetiratsetaam seondub näriliste ajukoe teatud spetsiifiliste sidumiskohtadega.
English: A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study.
Estonian: Uuringus kasutati raviskeemi 20 mg/kg päevas kuni 40 mg/kg päevas imikutel (1…6 kuu vanused) ja 25 mg/kg päevas kuni 50 mg/kg päevas imikutel ja lastel (6 kuud…4-aastased).
English: • partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age
Estonian: • partsiaalsete krampide korral koos sekundaarse generaliseerumisega või ilma täiskasvanutele, noorukitele ja imikutele alates 1. elukuust
English: The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam.
Estonian: Kõrvaltoimete kokkuvõte põhineb kõigi näidustuste ühendatud platseebo-kontrollitud kliinilistes uuringutes osalenud patsientide (kokku oli 3416 levetiratsetaamiga ravitud patsienti) koguandmetel.
English: Contains E216, E218, maltitol liquid (E965) and propylene glycol (E1520).
Estonian: Sisaldab E216, E218, vedelat maltitooli (E965) ja propüleenglükooli (E1520).
English: (4) Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.
Estonian: (4) Dialüüsi järgselt on soovitatav manustada täiendavalt 3,5-7 mg/kg (0,035-0,07 ml/kg).
English: Levetiracetam is not extensively metabolised in humans.
Estonian: Inimestel ei ole levetiratsetaami metabolism ulatuslik.
English: confusion, panic attack, emotional instability/mood swings, agitation;
Estonian: viha, segasus, emotsionaalne ebastabiilsus/meeleolu kõikumine, ärevus;
English: Dose in adults and adolescents from 16 years of age:
Estonian: Annustamine täiskasvanutele ja üle 16-aastastele noorukitele:
English: Instruction for use for 1 ml and 3 ml syringes with an adaptor
Estonian: Kasutamisjuhend 1 ml ja 3 ml süstlale adapteriga).
English: Levetiracetam Actavis Group is used: on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.
Estonian: Levetiracetam Actavis Group'i kasutatakse: - monoteraapiana teatud epilepsiavormi raviks alates 16-aastastel noorukitel ja täiskasvanutel, kellel on hiljuti diagnoositud epilepsia.
English: The 300 ml glass bottle of Levetiracetam Actavis Group (for children aged 4 years and above, adolescents and adults) is packed in a cardboard box containing a 10 ml oral syringe (graduated every 0.25 ml).
Estonian: Levetiracetam Actavis Group 300 ml klaaspudel (lastele vanuses alates 4 eluaastast, noorukitele ja täiskasvanutele) on pakitud pappkarpi koos 10 ml suukaudse süstlaga (gradueeritud iga 0,25 ml tagant).
English: Depending upon the clinical response and tolerability, the dose can be increased up to 21 mg/kg twice daily.
Estonian: Sõltuvalt klinilisest vastuses ja talubusest võib annust suurendada kuni 21 mg/kg kohta päevas.
English: The initial therapeutic dose is 500 mg twice daily.
Estonian: Esialgne annus on 500 mg kaks korda päevas.
English: Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the age, weight and dose.
Estonian: Arst peab välja kirjutama vanusele, kehakaalule ja annusele kõige sobivama levetiratsetaami ravimvormi.
English: In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants aged 1 month to less than 6 months.
Estonian: Et olla kindel annuse täpsuses kasutatakse seda pakendit 1-kuuste ja kuni 6-kuuste imikute puhul.
English: 300 ml oral solution with a 1 ml oral syringe and an adaptor.
Estonian: 300 ml suukaudset lahust, 1 ml süstal ja adaptor.
English: With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year.
Estonian: Pikaajalise jätkuravi kestel ei esinenud 47,4% patsientidest toonilis-kloonilisi krampe vähemalt 6 kuud ning 31,5%-l vähemalt 1 aasta jooksul.
English: The NOAEL (No Observed Adverse Effect Level) was 3,600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and 1,200 mg/kg/day for fetuses.
Estonian: NOAEL (No Observed Adverse Effect Level) oli tiinetel emasrottidel 3600 mg/kg päevas (mis vastab 12-kordsele soovituslikule maksimaalsele päevasele annusele inimesel mg/m2 kohta) ja loodetel 1200 mg/kg päevas.
English: If you forget to take Levetiracetam Actavis Group
Estonian: Kui te unustate Levetiracetam Actavis Group'i võtta
English: General dose: Levetiracetam Actavis Group is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml (500 mg) and 15 ml (1,500 mg).
Estonian: Tavaline annus: ravimit Levetiracetam Actavis Group võetakse kaks korda ööpäevas kahes võrdses annuses, kusjuures iga mõõdetud üksikannus on 5 ml (500 mg) kuni 15 ml (1500 mg).
English: If you take more Levetiracetam Actavis Group than you should
Estonian: Kui te võtate Levetiracetam Actavis Group'i rohkem kui ette nähtud
English: The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness.
Estonian: Kõige sagedamini teatatud kõrvaltoimed on ninaneelupõletik, somnolentsus (unisus), peavalu, väsimus ja pearinglus.
English: Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy:
Estonian: Täiendravi partsiaalsete krampide puhul koos sekundaarse generaliseerumisega või ilma, epilepsiaga täiskasvanutel, noorukitel, lastel ja imikutel alates 1. elukuust:
English: Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed.
Estonian: Pärast korduva suukaudse annuse (20…60 mg/kg/päevas) manustamist epilepsiaga lastele (4…12aastased) imendus levetiratsetaam kiiresti.
English: 300 ml oral solution with a 3 ml oral syringe and an adaptor.
Estonian: 300 ml suukaudset lahust, 3 ml süstal ja adaptor.
English: • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
Estonian: • müoklooniliste krampide korral täiskasvanutele ja alates 12-aastastele noorukitele juveniilse müokloonilise epilepsiaga
English: What Levetiracetam Actavis Group looks like and contents of the pack
Estonian: Kuidas Levetiracetam Actavis Group välja näeb ja pakendi sisu
English: For children aged 1 month to less than 6 months.
Estonian: 1-kuustele kuni 6-kuustele lastele.
English: With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year.
Estonian: Jätkuva pikaajalise ravi foonil olid 11,4% patsientidest krambivabad 6 kuud ning 7,2% patsientidest vähemalt 1 aasta.
English: From 50 kg
Estonian: Alates 50 kg
English: Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Estonian: Monoteraapia partsiaalsete krampide puhul koos sekundaarse generaliseerumisega või ilma, äsja diagnoositud epilepsiaga patsientidel alates 16. eluaastast.
English: Package Leaflet: Information for the patient Levetiracetam Actavis Group 100 mg/ml oral solution
Estonian: Pakendi infoleht: teave kasutajale Levetiracetam Actavis Group 100 mg/ml suukaudne lahus
English: Epilepsy is a condition where the patients have repeated fits (seizures).
Estonian: Epilepsia on haigus, millega kaasnevad korduvad krambihood.
English: Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m2.
Estonian: Seetõttu on kreatiniini kliirensi korral <60 ml/min/1,73m2, vaja päevast säilitusannust vähendada 50%.
English: Levetiracetam Actavis Group 100 mg/ml oral solution is a clear, faint yellowish-brown solution.
Estonian: Levetiracetam Actavis Group, 100 mg/ml suukaudne lahus on selge, kergelt kollakas-pruun lahus.
English: Abdominal pain, diarrhoea, dyspepsia, vomiting, nausea
Estonian: Kõhuvalu, diarröa, düspepsia, oksendamine, iiveldus
English: Diplopia, vision blurred
Estonian: Diploopia, hägune nägemine
English: • uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);
Estonian: raskused liigutuste kontrollimisel, hüperkineesia (hüperaktiivsus);
English: Dosing adjustment for infants, children and adolescent patients weighing less than 50 kg with impaired renal function:
Estonian: Annuse kohaldamine neerukahjustusega imikutel, lastel ja noorukitel kehakaaluga alla 50 kg:
English: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment.
Estonian: Levetiratsetaami manustamisega seoses on harvadel juhtudel kirjeldatud vähenenud vererakkude arvu (neutropeenia, agranulotsütoos, leukopeenia, trombotsütopeenia ja pantsütopeenia), mis esines üldjuhul ravi alguses.
English: for patients unable to swallow tablets or for the administration of doses below 250 mg.
Estonian: Lisaks peaks lastel kehakaaluga alla 25 kg ravi alustamiseks, patsientidel, kellel esineb tableti neelamisel raskusi ning alla 250 mg annuste puhul kasutama suukaudset lahust.
English: 300 ml oral solution with a 10 ml oral syringe.
Estonian: 300 ml suukaudset lahust, 10 ml süstal.
English: If you stop taking Levetiracetam Actavis Group
Estonian: Kui te lõpetate Levetiracetam Actavis Group võtmise
English: This leaflet was last revised in {month/YYYY}.
Estonian: Infoleht on viimati uuendatud:
English: The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.
Estonian: Toimeaine levetiratsetaam on pürrolidooni derivaat (α-etüül-2-okso-1-pürrolidiinatsetamiidi S
English: (5) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.
Estonian: (5) Dialüüsi järgselt on soovitatav manustada täiendavalt 5-10 mg/kg (0,05-0,10 ml/kg).
English: With continued long-term treatment, 8.6% of the patients were seizure-free for at least 6 months and 7.8 % were seizure-free for at least 1 year.
Estonian: Pikaajalise jätkuravi kestel ei esinenud 8,6% patsientidest krampe vähemalt 6 kuu ja 7,8% vähemalt 1 aasta jooksul.
English: Method of administration:
Estonian: Kasutusjuhend:
English: 6.5 Nature and contents of container
Estonian: 6.5 Pakendi iseloomustus ja sisu <ja spetsiaalsed vahendid kasutamiseks, manustamiseks või implanteerimiseks>
English: For children above 4 years, measure the appropriate dosage using the 10 ml syringe included in the package.
Estonian: Annus üle 4-aastastele lastele: mõõtke õige annus välja pakendisse lisatud 10 ml süstla abil.
English: Instruction for use: Instruction for use for 10 ml syringes
Estonian: 10 ml suukaudse süstla kasutusjuhend
English: • Levetiracetam Actavis Group is used as a chronic treatment.
Estonian: - Levetiracetam Actavis Group'i kasutatakse nö kroonilise ravina.